BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 21514251)

  • 21. Dual antiplatelet therapy in coronary artery disease: a case-based approach.
    Raymond C; Menon V
    Cleve Clin J Med; 2009 Nov; 76(11):663-70. PubMed ID: 19884296
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4).
    Bromberg-Marin G; Marin-Neto JA; Parsons LS; Canto JG; Rogers WJ;
    Am J Cardiol; 2006 Nov; 98(9):1125-31. PubMed ID: 17056312
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study).
    Patti G; Pasceri V; Vizzi V; Ricottini E; Di Sciascio G
    Am J Cardiol; 2011 Apr; 107(7):995-1000. PubMed ID: 21256470
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiplatelet therapy and percutaneous coronary intervention in patients with acute coronary syndrome and thrombocytopenia.
    Yusuf SW; Iliescu C; Bathina JD; Daher IN; Durand JB
    Tex Heart Inst J; 2010; 37(3):336-40. PubMed ID: 20548817
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy.
    Rossini R; Musumeci G; Lettieri C; Molfese M; Mihalcsik L; Mantovani P; Sirbu V; Bass TA; Della Rovere F; Gavazzi A; Angiolillo DJ
    Am J Cardiol; 2008 Dec; 102(12):1618-23. PubMed ID: 19064015
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clopidogrel for prevention of major cardiac events after coronary stent implantation: 30-day and 6-month results in patients with smaller stents.
    Calver AL; Blows LJ; Harmer S; Dawkins KD; Gray HH; Morgan JH; Simpson IA
    Am Heart J; 2000 Sep; 140(3):483-91. PubMed ID: 10966552
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
    Aronow HD; Steinhubl SR; Brennan DM; Berger PB; Topol EJ;
    Am Heart J; 2009 Feb; 157(2):369-74. PubMed ID: 19185647
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intensity of antiplatelet therapy in patients with acute coronary syndromes and percutaneous coronary intervention: the promise of prasugrel?
    Wiviott SD
    Cardiol Clin; 2008 Nov; 26(4):629-37. PubMed ID: 18929236
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Warfarin combined with blood platelet inhibition].
    Vik-Mo H
    Tidsskr Nor Laegeforen; 2011 Feb; 131(3):252-3. PubMed ID: 21304575
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pulmonary alveolar hemorrhage mimicking a pneumopathy: a rare complication of dual antiplatelet therapy for ST elevation myocardial infarction.
    Oualim S; Elharda CA; Benzeroual D; Hattaoui ME
    Pan Afr Med J; 2016; 24():308. PubMed ID: 28154663
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiplatelet therapy in the perioperative period.
    Václavík J; Táborský M
    Eur J Intern Med; 2011 Feb; 22(1):26-31. PubMed ID: 21238889
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
    Steg PG; James S; Harrington RA; Ardissino D; Becker RC; Cannon CP; Emanuelsson H; Finkelstein A; Husted S; Katus H; Kilhamn J; Olofsson S; Storey RF; Weaver WD; Wallentin L;
    Circulation; 2010 Nov; 122(21):2131-41. PubMed ID: 21060072
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness and safety of reduced-dose enoxaparin in non-ST-segment elevation acute coronary syndrome followed by antiplatelet therapy alone for percutaneous coronary intervention.
    Denardo SJ; Davis KE; Tcheng JE
    Am J Cardiol; 2007 Nov; 100(9):1376-82. PubMed ID: 17950793
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of chronic antiplatelet therapy before hospitalization on ischemic and bleeding events in invasively managed patients with acute coronary syndromes: the ACUITY trial.
    Ambrosio G; Steinhubl S; Gresele P; Tritto I; Zuchi C; Bertrand ME; Lincoff AM; Moses JW; Ohman EM; White HD; Mehran R; Stone GW
    Eur J Cardiovasc Prev Rehabil; 2011 Feb; 18(1):121-8. PubMed ID: 20523219
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Does dual antiplatelet therapy always require gastroprotection? Tailored medical therapy should prevail over the generalized prescription of proton pump inhibitors in patients on dual antiplatelet therapy].
    Marcucci R
    G Ital Cardiol (Rome); 2010 Jun; 11(6):481-7; discussion 487. PubMed ID: 20922874
    [No Abstract]   [Full Text] [Related]  

  • 36. A randomised determination of the Effect of Fluvastatin and Atorvastatin on top of dual antiplatelet treatment on platelet aggregation after implantation of coronary drug-eluting stents. The EFA-Trial.
    Wenaweser P; Eshtehardi P; Abrecht L; Zwahlen M; Schmidlin K; Windecker S; Meier B; Haeberli A; Hess OM
    Thromb Haemost; 2010 Sep; 104(3):554-62. PubMed ID: 20664903
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction.
    Buresly K; Eisenberg MJ; Zhang X; Pilote L
    Arch Intern Med; 2005 Apr; 165(7):784-9. PubMed ID: 15824298
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glycoprotein IIb-IIIa inhibitors in the emergency department for patients with non-ST-elevation acute coronary syndromes: principles and practices.
    Lefebvre CW; Hoekstra JW; Bonaca M; Giugliano R
    J Emerg Med; 2009 Feb; 36(2):162-70. PubMed ID: 18353601
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiplatelet options for secondary prevention in acute coronary syndromes.
    Silvain J; Cayla G; O'Connor SA; Collet JP; Montalescot G
    Expert Rev Cardiovasc Ther; 2011 Nov; 9(11):1403-15. PubMed ID: 22059790
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiplatelet agents used for early intervention in acute coronary syndrome: myocardial salvage versus bleeding complications.
    Aranki SF; Body SC
    J Thorac Cardiovasc Surg; 2009 Oct; 138(4):807-10. PubMed ID: 19769880
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.